Publications by authors named "M Dal Maschio"
Background: Notwithstanding guidance from the European Cystic Fibrosis (CF) Society (ECFS) neonatal screening (NBS) working group, significant variation persists in the evaluation and management of Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) subjects, leaving many aspects of care under debate. This study reports the results of a national survey investigating management and treatment approaches of pre-school CFSPIDs in Italy.
Methods: In February 2024, a comprehensive questionnaire was distributed to all Italian CF centers.
Brain tumor-related epilepsy (BTRE) is a rare disease in which brain tumor (BT) and epilepsy overlap simultaneously and can have a negative impact on a patient's neuropsychological, behavioral, and quality of life (QoL) spheres. In this review we (a) addressed the main neuropsychological, behavioral, and QoL issues that may occur in BTRE patients, (b) described how BT, BTRE, and their respective treatments can impact these domains, and (c) identified tools and standardized evaluation methodologies specific for BTRE patients. Neuropsychological disorders and behavioral issues can be direct consequences of BTRE and all related treatments, such as surgery, anti-cancer and anti-seizure medication, corticosteroids, etc.
View Article and Find Full Text PDFArticle Synopsis
- An evaluation compared the economic and clinical impact of mRNA-1273 versus BNT162b2 COVID-19 vaccines for immunocompromised individuals aged 30 and older in France during Fall 2023 and Spring 2024.
- * The study estimated outcomes like infections, hospitalizations, deaths, long COVID cases, costs, and quality-adjusted life years (QALYs) using a decision-analytic model, finding that mRNA-1273 vaccines offer greater protection.
- * In a scenario with full vaccine coverage, mRNA-1273 could prevent nearly 4,000 infections and 326 long COVID cases, resulting in €10.1 million in societal cost-savings and 645 additional QALYs.
Aims: To estimate the potential clinical impact and cost-effectiveness of a United Kingdom (UK) Autumn 2024 vaccination campaign with an updated Moderna COVID-19 vaccine in adults ≥65 years and eligible persons 6 months to 64 years of age over a 1-year time horizon (September 2024-August 2025).
Materials And Methods: A compartmental Susceptible-Exposed-Infected-Recovered model was adapted to reflect COVID-19 cases in the UK. Numbers of symptomatic infections, COVID-19-related hospitalizations and deaths, costs, and quality-adjusted life-years (QALYs) were predicted using a decision tree.